Immunovant (IMVT) Other Non-Current Assets (2019 - 2026)

Immunovant has reported Other Non-Current Assets for 5 years, with the latest figure at $7.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 0.81% year-over-year to $7.7 million; the trailing twelve-month figure through Mar 2026 stood at $7.7 million (up 0.81% YoY), and the FY2026 full-year result was $7.7 million, up 0.81% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $7.7 million, down from $8.9 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $8.9 million in Q2 2025, with the low at $7.6 million in Q4 2024.
• Historically, Other Non-Current Assets has averaged $8.2 million across 3 years, with a median of $7.7 million in 2026.
• Annual changes were most pronounced in 2025 — Other Non-Current Assets climbed 17.13% — and 2026, when it rose 0.81%.
• Immunovant's Other Non-Current Assets stood at $7.6 million in 2024, then increased by 17.13% to $8.9 million in 2025, then dropped by 13.92% to $7.7 million in 2026.
• The last three Other Non-Current Assets figures came in at $7.7 million (Q1 2026), $8.9 million (Q4 2025), and $8.8 million (Q3 2025), per Business Quant data.